Hanmi Pharm (KRX:128940) reported third-quarter net income attributable to shareholders of the parent company of 31 billion won, down 43.3% from 54.7 billion won a year earlier.
Sales for the quarter ended September was 362.1 billion won, declining 0.7% from 364.61 billion won in the year-ago period.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。